Systemic Therapies for mHSPC and Castrate Resistant Prostate Cancer episode artwork

EPISODE · Nov 9, 2022 · 37 MIN

Systemic Therapies for mHSPC and Castrate Resistant Prostate Cancer

from AUAUniversity · host American Urological Association

Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer Host: Jay D. Raman, MD, FACS Co-Host: Alicia Morgans, MD, MPH and Kelly Stratton, MD CME Available: auau.auanet.org/node/37317 At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Prioritize or stratify treatment options for metastatic prostate cancer. 3. Describe the mechanism of action and role of immune checkpoint inhibitors for advanced prostate cancer. 4. Identify management of side effects and adverse events that patients experience for systemic therapies for advanced prostate cancer. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme

Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer Host: Jay D. Raman, MD, FACS Co-Host: Alicia Morgans, MD, MPH and Kelly Stratton, MD CME Available: auau.auanet.org/node/37317 At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Prioritize or stratify treatment options for metastatic prostate cancer. 3. Describe the mechanism of action and role of immune checkpoint inhibitors for advanced prostate cancer. 4. Identify management of side effects and adverse events that patients experience for systemic therapies for advanced prostate cancer. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme

NOW PLAYING

Systemic Therapies for mHSPC and Castrate Resistant Prostate Cancer

0:00 37:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AUAUniversity?

This episode is 37 minutes long.

When was this AUAUniversity episode published?

This episode was published on November 9, 2022.

What is this episode about?

Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer Host: Jay D. Raman, MD, FACS Co-Host: Alicia Morgans, MD, MPH and Kelly Stratton, MD CME Available: auau.auanet.org/node/37317 At the...

Can I download this AUAUniversity episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!